• 作者：P. Fenollosa^a ; ^{fenollosa.pedro@gmail.com} ; C. de Barutell^b ; J. Figueroa^c ; A. Mí ; guez^c ; C. Nieto^d
• 关键词：Toxina botulí ; nica ; Dysport ; Estudio clí ; nico ; Sí ; ndrome de dolor miofascial ; Puntos gatillo ; Miofascial
• 刊名：Rehabilitaci贸n
• 出版年：2011
• 期刊代码：pca300_00487120
• 类别：med
• 出版时间：April-June 2011
• 卷：45
• 期：2
• 页码：139-147
• 文件大小：233 K

Introduction

It is postulated that botulinum toxin type A (BTA) is effective in the treatment of the myofascial pain syndrome (MPS). However, previous studies have shown contradictory results. Our objective has been to evaluate the efficacy and safety of a single dose of BTA (Dysport^庐) in primary MPS of cervical-dorsal localization.

Material and methods

A multicenter, randomized, double blind, parallel and placebo-controlled pilot study was performed. The participants (n = 24, 1:1 regime) were randomized to receive an intramuscular dose of Dysport^庐 (maximum dose: 500 U) or placebo, with follow-up for 12 weeks. Pain intensity using the visual analogue scale (VAS) and pressure pain threshold with the algometry were measured. All of the participants were told to perform muscle stretchings.

Results

The patients treated with placebo showed an initial decrease in pain intensity followed by a gradual increase of it while those who received Dysport^庐 show a slower, but more continued improvement. After 12 weeks, the mean reductions on the VAS were 26%and 44.6%, respectively. The reduction in the patients who were treated with Dysport^庐 was clinically relevant, although the difference between groups was not statistically significant. At 12 weeks, the pressure pain threshold had increased in both groups (36%placebo and 58%Dysport^庐; P=.748 between treatments). Similar tendencies were seen in all the trigger points. Treatment with Dysport^庐 was well tolerated.

Conclusions

These results suggest that Dysport^庐 is beneficial in the treatment of cervical-dorsal MPS.